Quarterly report pursuant to Section 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.5.0.2
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Increase in cost of goods sold due to reclassification $ 111,217 $ 70,799 $ 197,508 $ 123,823  
Decrease in selling, general and administrative expenses (111,217) (70,799) (197,508) (123,823)  
Net loss (2,226,902) (2,003,068) (3,760,019) (4,651,858)  
Cash flows from operations     (905,660) (3,826,247)  
Cash equivalents 0   0   $ 0
Cash in excess of FDIC limits 1,114,848   1,114,848    
Notes receivable 540,351   540,351   617,681
Allowance for doubtful accounts 100,000   100,000   100,000
Shipping and handling 111,217 70,799 197,508 123,823  
Allowance for customer returns 0 0 0 0  
Inventory 13,566,412   13,566,412   $ 14,133,920
Depreciation expense 48,690 49,318 97,715 93,543  
Research and development expense 341,547 433,544 $ 483,360 $ 744,022  
Options [Member]          
Potentially dilutive shares outstanding     10,919,985 6,749,444  
Warrants [Member]          
Potentially dilutive shares outstanding     2,000,000    
Accounts Receivable [Member] | One Customer [Member]          
Concentration risk percentage     61.00%    
Accounts Receivable [Member] | Two Customers [Member]          
Concentration risk percentage         83.00%
Germany and The Netherlands [Member]          
Inventory 7,587,136   $ 7,587,136    
Pharmaceutical Segment [Member]          
Capital required over next 12 months     1,500,000    
Consumer Products Segment [Member]          
Research and development expense 224,266 433,544 366,079 $ 744,022  
Specialty Pharmaceutical Segment [Member]          
Research and development expense $ 117,281 $ 0 $ 117,281 $ 0